Case report of amiodarone-associated allergic pneumonitis amidst the COVID-19 pandemic.
Rev Cardiovasc Med
; 22(1): 181-184, 2021 03 30.
Article
in English
| MEDLINE | ID: covidwho-1168428
ABSTRACT
Amiodarone is a common antiarrhythmic drug that is utilised in clinical practice and is associated with pulmonary toxicity. The most common form of pulmonary complication is interstitial pneumonitis which is treated with discontinuation of amiodarone and initiation of corticosteroids. Amiodarone-induced pulmonary eosinophilia is a rare complication of amiodarone therapy, with blood and pulmonary eosinophilia the predominant features. During the COVID-19 era, the incidence of delay in treatment of pulmonary pathology is also delayed due to the effort of excluding COVID-19 infection. Here we report a case of a 64-year-old man who developed eosinophilic pneumonia after initiation of amiodarone therapy, and the investigations required to exclude other forms of pulmonary toxicity. We also reviewed the effect of COVID-19 testing in the management of patients presenting with respiratory distress.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Alveolitis, Extrinsic Allergic
/
COVID-19 Testing
/
COVID-19
/
Amiodarone
/
Anti-Arrhythmia Agents
Type of study:
Case report
/
Diagnostic study
/
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Rev Cardiovasc Med
Journal subject:
Vascular Diseases
/
Cardiology
Year:
2021
Document Type:
Article
Affiliation country:
J.rcm.2021.01.267
Similar
MEDLINE
...
LILACS
LIS